Kanghong Pharmaceutical: Pirfenidone tablets are expected to be selected in the 12th batch of national drug procurement.

Kanghong Pharmaceutical announced that on July 31, 2026, the company's Pirfenidone tablets will be included in the "Proposed Selection Results of the 12th Batch of National Organization Drug Centralized Procurement," with a specification of 2mg, 28 tablets per box, for the treatment of epilepsy. The procurement cycle for each variety nationwide will extend until December 31, 2029. If procurement contracts are signed and implemented subsequently, it will expand the product sales scale, enhance brand influence, and have a positive impact on performance. However, there is uncertainty regarding the signing of procurement contracts and the execution of market sales.